Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2-Reference-Cited by-同舟云学术

Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2

Published:2013-12-21 Issue:3 Volume:143 Page:459-467
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Beck J. Thaddeus,Hortobagyi Gabriel N.,Campone Mario,Lebrun Fabienne,Deleu Ines,Rugo Hope S.,Pistilli Barbara,Masuda Norikazu,Hart Lowell,Melichar Bohuslav,Dakhil Shaker,Geberth Matthias,Nunzi Martina,Heng Daniel Y. C.,Brechenmacher Thomas,El-Hashimy Mona,Douma Shyanne,Ringeisen Francois,Piccart Martine

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-013-2814-5.pdf

Reference35 articles.

1. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A (2011) Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 125(1–2):13–22. doi: 10.1016/j.jsbmb.2011.02.001

2. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123(1):21–27. doi: 10.1309/4WV79N2GHJ3X1841

3. Mohd Sharial MS, Crown J, Hennessy BT (2012) Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 23(12):3007–3016. doi: 10.1093/annonc/mds200

4. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van’t Veer L, Viale G, Krop I, Winer E (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21(3):242–252. doi: 10.1016/j.breast.2012.03.003

5. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii11–19. doi: 10.1093/annonc/mds232

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer;Anticancer Research;2024-03-27

2. The Different Sequences of Cdk4/6 Inhibitor and Mtor Inhibitor in Hr+/Her2- Advanced Breast Cancer: A Multicenter Real-World Study;2024

3. The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions;Journal of Clinical Medicine;2023-09-16

4. FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation;Frontiers in Oncology;2023-05-03

5. Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges;Biomedicines;2023-01-01